{"id":"NCT02850965","sponsor":"Boehringer Ingelheim","briefTitle":"Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis","officialTitle":"Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-08-17","primaryCompletion":"2018-01-17","completion":"2018-01-17","firstPosted":"2016-08-01","resultsPosted":"2019-02-08","lastUpdate":"2019-02-08"},"enrollment":318,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"BI 695501","otherNames":[]},{"type":"DRUG","name":"Humira","otherNames":[]}],"arms":[{"label":"BI 695501","type":"EXPERIMENTAL"},{"label":"Humira","type":"ACTIVE_COMPARATOR"}],"summary":"To evaluate the efficacy and to compare efficacy and safety of BI 695501 versus Humira in patients with moderate to severe chronic plaque psoriasis.","primaryOutcome":{"measure":"The Percentage of Patients With at Least 75% Reduction in Psoriasis Area and Severity Index (PASI 75) Response at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"BI 695501","deltaMin":68.2,"sd":null},{"arm":"US-licensed Humira","deltaMin":70.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":24},"locations":{"siteCount":54,"countries":["United States","Czechia","Estonia","Germany","Poland","Russia","Slovakia","Ukraine"]},"refs":{"pmids":["40498294","39551590","33317345"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":159},"commonTop":["Nasopharyngitis","Injection site erythema","Injection site pain"]}}